Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10843358 | 0.90 | NOTUM (0.46) | NOTUMADRA2ACYP2D6ADRA2BADRA2C | |
| SCHEMBL746562 | 0.84 | NOTUM (0.44) | NOTUMADRA2ACYP2D6ADRA2BADRA2C | |
| SCHEMBL21257665 | 0.81 | ADRA2A (0.42) | NOTUMADRA2ACYP2D6ADRA2BADRA2C | |
| SCHEMBL424738 | 0.80 | NOTUM (0.47) | NOTUMAADATTRPV1 | |
| SCHEMBL16110071 | 0.80 | TRPV1 (0.40) | TRPV1 | |
| SCHEMBL3600670 | 0.80 | TRPV1 (0.40) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL24265742 | 0.79 | TRPV1 (0.39) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8557973 | 0.79 | NOTUM (0.49) | NOTUMAADATTRPV1 | |
| SCHEMBL3600672 | 0.79 | TRPV1 (0.42) | CYP2D6ADRA2CADRA1APOLBTRPV1 | |
| SCHEMBL9653024 | 0.79 | TRPV1 (0.42) | POLBTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773207-B1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-03-07 | — | — | EP | claimed |
| US-9221809-B2 | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-12-29 | — | — | US | claimed |
| US-20140329799-A1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-11-06 | — | — | US | claimed |
| EP-3212630-B1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-05-18 | — | — | EP | disclosed |
| CN-106604917-B | Novel dihydroquinoline pyrazolyl compounds as aldosterone synthase inhibitors | 豪夫迈·罗氏有限公司 | 2020-10-09 | — | — | CN | disclosed |
| EP-3212631-B1 | PYRAZOLYL-3,4-DIHYDROQUINOLIN-2-ONE ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2020-02-12 | — | — | EP | disclosed |
| EP-3212638-B1 | NEW DIHYDROQUINOLINE PYRAZOLYL COMPOUNDS AS ALDOSTERONE SYNTHASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-9796726-B2 | Dihydroquinoline pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796726-B2 | Dihydroquinoline pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796702-B2 | Dihydroquinoline pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796702-B2 | Dihydroquinoline pyrazolyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9012457-B2 | 2-carboxamide-4-piperazinyl-benzofuran derivative | ASTRAZENECA AB (SE) | 2015-04-21 | — | — | US | disclosed |
| US-9012457-B2 | 2-carboxamide-4-piperazinyl-benzofuran derivative | ASTRAZENECA AB (SE) | 2015-04-21 | — | — | US | disclosed |
| US-9012457-B2 | 2-carboxamide-4-piperazinyl-benzofuran derivative | ASTRAZENECA AB (SE) | 2015-04-21 | — | — | US | disclosed |
| US-20140329830-A1 | 2-CARBOXAMIDE-4-PIPERAZINYL-BENZOFURAN DERIVATIVE | ASTRAZENECA AB (SE) | 2014-11-06 | — | — | US | disclosed |
| US-20140329830-A1 | 2-CARBOXAMIDE-4-PIPERAZINYL-BENZOFURAN DERIVATIVE | ASTRAZENECA AB (SE) | 2014-11-06 | — | — | US | disclosed |
| US-20140329830-A1 | 2-CARBOXAMIDE-4-PIPERAZINYL-BENZOFURAN DERIVATIVE | ASTRAZENECA AB (SE) | 2014-11-06 | — | — | US | disclosed |
| EP-2655365-A1 | 2-CARBOXAMIDE-4-PIPERAZINYL-BENZOFURAN DERIVATIVE | AstraZeneca AB (SE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012087229-A1 | 2-CARBOXAMIDE-4-PIPERAZINYL-BENZOFURAN DERIVATIVE | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087229-A1 | 2-CARBOXAMIDE-4-PIPERAZINYL-BENZOFURAN DERIVATIVE | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329799-A1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | IRAK4, IRAK1, IRAK2 | NOTUM 4064/4885ADRA2A 3423/4885CYP2D6 1795/4885 |
| US-20140329830-A1 | 2-CARBOXAMIDE-4-PIPERAZINYL-BENZOFURAN DERIVATIVE | GRIN2C, BDNF, GRIN2A | NOTUM 1090/4885ADRA2A 727/4885CYP2D6 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.